Aclaris Therapeutics Stock Investor Sentiment

ACRS Stock  USD 3.63  0.28  7.16%   
Slightly above 52% of Aclaris Therapeutics' private investors are presently thinking to get in. The analysis of overall sentiment of trading Aclaris Therapeutics stock suggests that some investors are interested at this time. Aclaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Aclaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Aclaris Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Aclaris Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at finance.yahoo.com         
BioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue Estimates
Yahoo News
over six months ago at www.macroaxis.com         
Disposition of 3531 shares by Joseph Monahan of Aclaris Therapeutics at 1.24 subject to Rule 16b-3
Macroaxis News
over six months ago at simplywall.st         
Were Keeping An Eye On Aclaris Therapeutics Cash Burn Rate
Simply Wall St News at Macroaxis
over six months ago at simplywall.st         
Acquisition by Walker Neal of 9467 shares of Aclaris Therapeutics subject to Rule 16b-3
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Aclaris Therapeutics, Inc. Given Consensus Rating of Hold by Brokerages - Defense World
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 9467 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at finance.yahoo.com         
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results onMay 7, 2024 and to Provide C...
Yahoo News
over six months ago at benzinga.com         
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide ...
benzinga news
over six months ago at news.google.com         
BML Capital Management LLC Purchases New Shares in Aclaris Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP as Chief Executive Officer
Yahoo News
over six months ago at news.google.com         
Aclaris Therapeutics, Inc. Shares Bought by Vanguard Group Inc. - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Favourable Signals For Aclaris Therapeutics Numerous Insiders Acquired Stock
Yahoo News
over six months ago at news.google.com         
Aclaris Therapeutics, Inc. Given Consensus Recommendation of Hold by Analysts - Defense World
Google News at Macroaxis
over six months ago at zacks.com         
Are Medical Stocks Lagging Aclaris Therapeutics This Year?
zacks News
over six months ago at finance.yahoo.com         
Are Medical Stocks Lagging Aclaris Therapeutics This Year?
Yahoo News
Far too much social signal, news, headlines, and media speculation about Aclaris Therapeutics that are available to investors today. That information is available publicly through Aclaris media outlets and privately through word of mouth or via Aclaris internal channels. However, regardless of the origin, that massive amount of Aclaris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aclaris Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aclaris Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aclaris Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aclaris Therapeutics alpha.

Aclaris Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 9467 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3
10/01/2024
2
Aclaris Therapeutics Inc Reports Q3 2024 Revenue at 4.35M, EPS Loss of 0.11, Misses Estimates
11/06/2024
3
Aclaris Therapeutics Announces 80 Million Private Placement
11/18/2024
4
Jefferies says buy this pharmaceutical play, sees more than 100 percent upside from here
11/19/2024
5
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies
11/20/2024
6
Disposition of 9466 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3
11/29/2024
7
Acquisition by Hugh Davis of 107000 shares of Aclaris Therapeutics subject to Rule 16b-3
12/02/2024
8
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635
12/03/2024
9
Disposition of 118840 shares by Walker Neal of Aclaris Therapeutics at 1.52 subject to Rule 16b-3
12/04/2024
10
Jacobs Levy Equity Management Inc. Takes 1.05 Million Position in Aclaris Therapeutics, Inc. - MarketBeat
12/09/2024

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.